New Strong Buy Stocks for August 31st

This reads more like a factor signal than a durable fundamental call: estimate revisions can drive 2-6 week price momentum, but they only become investable when they coincide with an operating inflection. The best setup is in names where expectations were too low and the next print can confirm margin repair; that favors a tactical squeeze in CBRL and, to a lesser extent, CNC. By contrast, TGT and VAC need evidence of share/occupancy recovery, not just cleaner P&L optics, or the market will eventually re-rate them back to cyclical value traps.

Second-order effects matter. In retail, any improvement at TGT that comes from inventory discipline or easier shrink math can pressure suppliers and peers via price competition rather than signal stronger end demand; WMT and COST are still the cleaner beneficiaries of a weak-consumer share shuffle. In managed care, CNC upside is mostly about medical-cost trend normalization and Medicaid rate timing; that can spill into the broader health-insurance complex, but the real catalyst is next quarter’s MLR and state rate notices, not the Zacks screen itself.

Contrarian view: the crowd may be overreading revision momentum as a quality upgrade. For CBRL and VAC especially, the market can get excited about earnings revisions while ignoring leverage to traffic, financing costs, and consumer confidence—meaning the move can reverse quickly if the next data point disappoints. Falsifiers are straightforward: weak comp sales for CBRL/TGT, rising MLR for CNC, higher catastrophe losses for HRTG, or no improvement in financing/occupancy metrics for VAC over the next 1-3 months.